DaBomb Protein Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	192.57	253.59	379.99	195.18	197.14	265.61
Trading Asset Securities	-	-	0.08	-	-	-
Cash & Short-Term Investments	192.57	253.59	380.07	195.18	197.14	265.61
Cash Growth	-31.66%	-33.28%	94.73%	-0.99%	-25.78%	28.71%
Accounts Receivable	31.15	32.28	51.25	36.99	56.04	49.4
Other Receivables	1.96	2.76	1.08	1.44	1.07	1.02
Receivables	33.11	35.05	52.34	38.42	57.11	50.42
Inventory	25.07	34.07	20.23	52.79	37.68	55.69
Prepaid Expenses	4.92	3.87	4.89	19.54	39.97	41.73
Other Current Assets	27.39	327.59	321.31	36.84	69.73	47.91
Total Current Assets	283.06	654.16	778.83	342.76	401.62	461.35
Property, Plant & Equipment	869.89	621.59	564.83	888.09	876.14	586.15
Long-Term Investments	-	-	-	0.18	0.04	-
Other Intangible Assets	0.19	0.21	0.19	0.28	0.37	1.44
Long-Term Deferred Tax Assets	7.27	8.55	12.31	13.85	9.2	0.89
Other Long-Term Assets	30.22	30.76	45.74	34.92	49.12	7.34
Total Assets	1,191	1,315	1,402	1,280	1,336	1,057
Accounts Payable	15.81	13.9	9.14	28.5	10.47	22.58
Accrued Expenses	7.42	17.8	11.05	11.8	17.22	18.74
Short-Term Debt	66.9	90	92	95	161	207.5
Current Portion of Long-Term Debt	29.06	30.98	238.29	66.66	18.47	-
Current Portion of Leases	0.61	1.14	0.98	1.37	1.51	1.49
Current Income Taxes Payable	-	-	-	-	-	3.72
Current Unearned Revenue	-	-	0.23	2.4	-	-
Other Current Liabilities	18.85	25.16	5.08	12.64	13.86	16.8
Total Current Liabilities	138.65	178.98	356.77	218.37	222.53	270.83
Long-Term Debt	24.26	45.41	85.7	330.94	433.22	78.22
Long-Term Leases	0.22	0.6	0.63	1.61	3.81	5.32
Long-Term Unearned Revenue	0.07	0.22	0.65	1.42	2.41	1.8
Long-Term Deferred Tax Liabilities	0.85	0.75	0.08	0.55	0.28	0.48
Total Liabilities	164.04	225.96	443.83	552.88	662.24	356.66
Common Stock	719.42	679.86	597.1	395.14	330.82	301.31
Additional Paid-In Capital	338.7	355.25	344.46	286.31	246.9	252.73
Retained Earnings	-10.96	26.31	4.3	61.32	105.98	174.46
Comprehensive Income & Other	-20.57	27.89	12.21	-15.56	-9.46	-27.98
Shareholders' Equity	1,027	1,089	958.06	727.2	674.24	700.51
Total Liabilities & Equity	1,191	1,315	1,402	1,280	1,336	1,057
Total Debt	121.05	168.13	417.6	495.59	618.01	292.53
Net Cash (Debt)	71.52	85.45	-37.53	-300.41	-420.87	-26.93
Net Cash Growth	180.57%	-	-	-	-	-
Net Cash Per Share	1.00	1.19	-0.70	-7.76	-12.96	-0.83
Filing Date Shares Outstanding	71.94	67.99	59.71	39.51	33.08	33.14
Total Common Shares Outstanding	71.94	67.99	59.71	39.51	33.08	33.14
Working Capital	144.4	475.19	422.07	124.39	179.09	190.52
Book Value Per Share	14.27	16.02	16.05	18.40	20.38	21.14
Tangible Book Value	1,026	1,089	957.88	726.92	673.88	699.07
Tangible Book Value Per Share	14.27	16.02	16.04	18.40	20.37	21.09
Land	401.07	401.07	401.07	401.07	400.92	108.92
Buildings	308.66	138.81	133.06	320.83	317.42	314.32
Machinery	341.89	187.52	177.46	291.48	256.69	238.67
Construction In Progress	1.48	51.76	-	0.24	1.42	0.74
Leasehold Improvements	50.67	25.83	25.31	54.72	53.41	52.84

Source: S&P Global Market Intelligence. Standard template. Financial Sources.